Antibody engineering for increased potency, breadth and half-life

Current Opinion in HIV and AIDS

Volumn 10, Issue 3, 2015, Pages 151-159

  Sievers, Stuart A ^a   Scharf, Louise ^a   West, Anthony P ^a   Bjorkman, Pamela J ^a,b  

^a California Institute of Technology   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

bispecific reagents; breadth; HIV 1; Keywords antibody engineering; polyreactivity; potency

Indexed keywords

BISPECIFIC ANTIBODY; FC RECEPTOR; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; REAGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; BIOINFORMATICS; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MOLECULAR LIBRARY; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; REVIEW; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; HUMAN; MOUSE; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, BISPECIFIC; BINDING SITES; HIV ANTIBODIES; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN ENGINEERING;

EID: 84928564663     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000148     Document Type: Review

References (112)

1. Lyumkis D, Julien JP, de Val N, et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1484-1490.
2. Julien JP, Cupo A, Sok D, et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013; 342:1477-1483.
3. Bohne-Lang A, von der Lieth CW. GlyProt: in silico glycosylation of proteins. Nucleic Acids Res 2005; 33:W214-219.
4. Pancera M, Zhou T, Druz A, et al. Structure and immune recognition of trimeric prefusion HIV-1 Env. Nature 2014; 514:455-461.
5. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
6. Kwong PD, Doyle ML, Casper DJ, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420:678-682.
7. Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77:10557-10565.
8. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
9. Wyatt R, Desjardin E, Olshevsky U, et al. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol 1997; 71:9722-9731.
10. Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 1996; 70:1863-1872.
11. Starcich BR, Hahn BH, Shaw GM, et al. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 1986; 45:637-648.
12. Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog 2010; 6:e1000908.
13. Galimidi RP, Klein JS, Politzer MS, et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 2015; 160:433-446.
14. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.
15. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861.
16. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640.
17. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
18. Balazs AB, Chen J, Hong CM, et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 48:81-88.
19. Johnson PR, Schnepp BC, Zhang JC, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15:901-906.
20. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
21. Barouch DH, Whitney JB, Moldt B, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503:224-228.
22. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-122.
23. Shingai M, Nishimura Y, Klein F, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503:277-280.
24. Halper-Stromberg A, Lu CL, Klein F, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989-999.
25. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412-425.
26. Scharf L, Scheid JF, Lee JH, et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 2014; 7:785-795.
27. Blattner C, Lee JH, Sliepen K, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014; 40:669-680.
28. Falkowska E, Le KM, Ramos A, et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014; 40:657-668.
29. Zhang MY, Yuan T, Li J, et al. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One 2012; 7:e44241.
30. Huang J, Kang BH, Pancera M, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014; 515:138-142.
31. Koellhoffer JF, Higgins CD, Lai JR. Protein engineering strategies for the development of viral vaccines and immunotherapeutics. FEBS Lett 2014; 588:298-307.
32. Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011; 3:243-252.
33. Korpimaki T, Rosenberg J, Virtanen P, et al. Further improvement of broad specificity hapten recognition with protein engineering. Protein Eng 2003; 16:37-46.
34. Garcia-Rodriguez C, Levy R, Arndt JW, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007; 25:107-116.
35. Sui J, Aird DR, Tamin A, et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 2008; 4:e1000197.
36. Clark LA, Boriack-Sjodin PA, Eldredge J, et al. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci 2006; 15:949-960.
37. Barderas R, Desmet J, Timmerman P, et al. Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci U S A 2008; 105:9029-9034.
38. Lippow SM, Tidor B. Progress in computational protein design. Curr Opin Biotechnol 2007; 18:305-311.
39. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007; 25:1171-1176.
40. Yang WP, Green K, Pinz-Sweeney S, et al. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995; 254:392-403.
41. Barbas CF 3rd, Hu D, Dunlop N, et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 1994; 91:3809-3813.
42. Zhang MY, Shu Y, Rudolph D, et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 2004; 335:209-219.
43. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat Rev Immunol 2013; 13:693-701.
44. West AP Jr, Scharf L, Scheid JF, et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014; 156:633-648.
45. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013; 153:126-138.
46. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333:1633-1637.
47. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-470.
48. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329:811-817.
49. Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805.
50. Wu X, Zhou T, Zhu J, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333:1593-1602.
51. Xiao X, Chen W, Feng Y, Dimitrov DS. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009; 1:802-817.
52. Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 2014; 192:1100-1106.
53. West AP Jr, Diskin R, Nussenzweig MC, Bjorkman PJ. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A 2012; 109:E2083-E2090.
54. Rudicell RS, Kwon YD, Ko SY, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 2014; 88:12669-12682.
55. Diskin R, Scheid JF, Marcovecchio PM, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011; 334:1289-1293.
56. Diskin R, Klein F, Horwitz JA, et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J Exp Med 2013; 210:1235-1249.
57. Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 2012; 109:E3268-E3277.
58. Garces F, Sok D, Kong L, et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 2014; 159:69-79.
59. Sok D, van Gils MJ, Pauthner M, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A 2014; 111:17624-17629.
60. Li Y, O'Dell S, Walker LM, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol 2011; 85:8954-8967.
61. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28:157-159.
62. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013; 20:804-813.
63. Chen J, Frey G, Peng H, et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 2014; 88:1249-1258.
64. Eisen HN, Chakraborty AK. Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A 2010; 107:22373-22380.
65. Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci 2012; 69:1435-1445.
66. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004; 25:174-179.
67. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435:590-597.
68. Tsuiji M, Yurasov S, Velinzon K, et al. A checkpoint for autoreactivity in human IgM memory B cell development. J Exp Med 2006; 203:393-400.
69. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-1377.
70. Zhou ZH, Wild T, Xiong Y, et al. Polyreactive antibodies plus complement enhance the phagocytosis of cells made apoptotic by UV-light or HIV. Sci Rep 2013; 3:2271.
71. Zhou ZH, Zhang Y, Hu YF, et al. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 2007; 1:51-61.
72. Zandman-Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1:329-337.
73. Kopelman RG, Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84:82-88.
74. Solinger AM, Adams LE, Friedman-Kien AE, Hess EV. Acquired immune deficiency syndrome (AIDS) and autoimmunity-mutually exclusive entities? J Clin Immunol 1988; 8:32-42.
75. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
76. Morris L, Chen X, Alam M, et al. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 2011; 6:e23532.
77. Liao HX, Chen X, Munshaw S, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011; 208:2237-2249.
78. Alam SM, McAdams M, Boren D, et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007; 178:4424-4435.
79. Matyas GR, Beck Z, Karasavvas N, Alving CR. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta 2009; 1788:660-665.
80. Dennison SM, Anasti K, Scearce RM, et al. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol 2011; 85:1340-1347.
81. Ofek G, Tang M, Sambor A, et al. Structure and mechanistic analysis of the antihuman immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78:10724-10737.
82. Yang G, Holl TM, Liu Y, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med 2013; 210:241-256.
83. Finton KA, Larimore K, Larman HB, et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 2013; 9:e1003639.
84. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012; 491:406-412.
85. Liu M, Yang G,Wiehe K, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 2015; 89:784-798.
86. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467:591-595.
87. Mouquet H, Klein F, Scheid JF, et al. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoS One 2011; 6:e24078.
88. Hotzel I, Theil FP, Bernstein LJ, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs 2012; 4:753-760.
89. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996; 26:690-696.
90. Israel EJ, Wilsker DF, Hayes KC, et al. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology 1996; 89:573-578.
91. Ko SY, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014; 514:642-645.
92. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultrapotent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-665.
93. Pepinsky RB, Silvian L, Berkowitz SA, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010; 19:954-966.
94. Sievers SA, Patel SN, Bennett K, et al. Engineering antibodies to enhance activity and increase half-life. AIDS Res Human Retroviruses 2014; 30:A210-A1210.
95. Chennamsetty N, Voynov V, Kayser V, et al. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A 2009; 106:11937-11942.
96. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. Aggregationresistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 2012; 25:591-601.
97. Perchiacca JM, Lee CC, Tessier PM. Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Eng Des Sel 2014; 27:29-39.
98. Kwon YD, Georgiev IS, Zhang B, et al. Enhancing the solubility of HIV-1-neutralizing Antibody 10E8. AIDS Res Human Retroviruses 2014; 30:A150-A1150.
99. Lacek K, Urbanowicz RA, Troise F, et al. Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. J Biol Chem 2014; 289:35015-35028.
100. Gavrilyuk J, Ban H, Uehara H, et al. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J Virol 2013; 87:4985-4993.
101. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003; 77:2859-2865.
102. Dey B, Liu L, Patel B, et al. Towards a functional cure of HIV Infection using a novel CD4-based chimeric antigen receptor. J Antivir Antiretrovir 2014; 6:72.
103. West AP Jr, Galimidi RP, Foglesong CP, et al. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive antihuman immunodeficiency virus reagents. J Virol 2010; 84:261-269.
104. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11:533-539.
105. ChenW, Feng Y, Prabakaran P, et al. Exceptionally potent and broadly crossreactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 2014; 88:1125-1139.
106. Chen W, Zhu Z, Feng Y, Dimitrov DS. Humandomain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 2008; 105:17121-17126.
107. Schaefer W, Regula JT, Bahner M, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-11192.
108. Craig RB, Summa CM, Corti M, Pincus SH. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One 2012; 7:e46778.
109. Quinlan BD, Joshi VR, Gardner MR, et al. A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4-and coreceptor-binding sites of gp120. J Virol 2014; 88:3353-3358.
110. Pace CS, Song R, Ochsenbauer C, et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A 2013; 110:13540-13545.
111. Sun M, Pace CS, Yao X, et al. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J Acquir Immune Defic Syndr 2014; 66:473-483.
112. Schnepp BC, Johnson PR. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS 2014; 9:250-256.